NEW YORK — French diagnostics firm HalioDx said on Thursday that it has signed an agreement for the distribution of its Immunoscore colon cancer risk-assessment test in Brazil with Diagnosticos da America (DASA).
According to HalioDx, Immunoscore is designed to predict the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites, helping to guide treatment strategies.
Under the terms of the deal, Sao Paulo-based DASA will have the exclusive distribution rights to the test in Brazil, offering it through its over 40 laboratory networks. Additional terms were not disclosed.
In early 2019, HalioDx struck an exclusive distribution deal for Immunoscore in China with Genecast. In September, it started collaborating with the Francophone Federation of Digestive Oncology to use the test to select patients for a colorectal cancer treatment clinical study.